Dan Bradbury has served as Chairman of the Castle Biosciences Board of Directors since September 2014, and as a director since 2012. He was an advisor to the company from 2008 until becoming a director. Mr. Bradbury is a life sciences executive with over 30 years of experience creating and implementing strategies that transform businesses, bring novel medicines to market and maximize shareholder value. He is the Managing Member of BioBrit, LLC, a life sciences consulting and investment firm.
Mr. Bradbury is the former President, Chief Executive Officer and Director of Amylin Pharmaceuticals, a biopharmaceutical company based in San Diego, CA, focused on metabolic diseases. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes and was listed on the Nasdaq 100. He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company for $7 billion in August 2012. Before joining Amylin, Dan worked in marketing and sales roles for ten years at SmithKline Beecham Pharmaceuticals. He serves on the board of directors of Biocon Limited, Corcept Therapeutics, Geron Corporation, and Intercept Pharmaceuticals, Inc. Mr. Bradbury also serves as a director for several private companies including DiaVacs, Inc., Equillium, Inc., Liquid Grids, Inc., Microdermis, Inc., NeuroVia, Inc., ProSciento, Inc. (formerly Profil Institute of Clinical Research, Inc.), Renova Therapeutics and Sensulin, Inc. He also serves on the board of the Riecken Community Libraries, the board of trustees of the Keck Graduate Institute, the BioMed Ventures Advisory Committee, the University of California San Diego’s Rady School of Management’s Advisory Council, the board of ADCY5.org, the Pharming Group N.V. Commercial Advisory Board, the ProLynx, LLC Advisory Board, the Arctic Aurora Life Science Advisory Board and is an advisor to Patricia Industries (a part of Investor AB).
Mr. Bradbury currently serves on the University of California San Diego’s Rady School of Management’s Advisory Council, the RAND Health Board of Advisors and the University of Miami’s Innovation Corporate Advisory Council. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom.
A leader in the biopharmaceutical industry for the past 25 years, Derek Maetzold founded Castle Biosciences in 2007 and has successfully overseen the discovery, development and commercialization of five diagnostic and prognostic tests in cancers, with more in the pipeline. Mr. Maetzold founded the company after a career of successive leadership roles at Encysive Pharmaceuticals, Schering Corporation (now Merck), Integrated Communications, Amylin Pharmaceuticals (now part of AstraZeneca) and Sandoz (now Novartis).
Mr. Maetzold started in field sales, and has served in roles that span the disciplines of marketing, new product development, business development, and commercialization strategy. Previously, he served as Officer and Vice President, Marketing and Sales, at Encysive Pharmaceuticals.
He attended George Mason University, where he received a BS in Biology, and completed additional coursework at the University of Calgary Health Sciences Center and the MBA program at University of California-Riverside. Mr. Maetzold is a published author, and a co-inventor of a number of technologies at Castle Biosciences and Encysive Pharmaceuticals.
Bonnie H. Anderson has served as a director for Castle Biosciences since June 2015. She is Chief Executive Officer and Chairman of the Board of Veracyte, a pioneering genomic diagnostics company that improves the lives of patients by reducing diagnostic ambiguity in healthcare. Her career spans over 30 years in regulated diagnostics and life science markets. Ms. Anderson cofounded Veracyte in 2008 and served as the company’s President and Chief Executive Officer until 2016, when she was also appointed Chairman of the Board. She took the company public in 2013 and has spearheaded Veracyte’s commercialization successes to date. Veracyte’s genomic tests are setting new standards in thyroid and lung cancer diagnosis, where they have helped tens of thousands of patients avoid unnecessary surgery.
Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter. She serves on the board of Castle Biosciences and on the steering committee for the Coalition for 21st Century Medicine and is a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. She graduated from Indiana University of Pennsylvania with a BS in Medical Technology and in 2012 was honored with a “Distinguished Alumni” award. In 2015, she was featured in Fast Company magazine’s “100 Most Creative People in Business,” and in 2014 was named one of the “Bay Area’s Most Admired CEOs” by the San Francisco Business Times. In 2013 she received the Silicon Valley Business Journal’s “Women of Influence” award.
Mara Aspinall has served as a director for Castle Biosciences since February 2015. She is the former President and CEO of Ventana Medical Systems, a member of the Roche Group—a worldwide leader in the development, manufacturing and commercialization of tissue-based cancer diagnostic products that enable personalized healthcare to patients. During her tenure, Ventana became the world’s leading oncology companion diagnostics developer and manufacturer.
Previously, Ms. Aspinall spent 12 years with Genzyme Corporation where she was President of Genzyme Genetics and President of Genzyme Pharmaceuticals. She was also the Founder, CEO and Director of On-Q-ity, a diagnostic company focused on transforming cancer patient management through the capture of circulating tumor cells (CTCs) in a patient’s blood.
A dynamic participant in the life sciences community, Ms. Aspinall has spearheaded many initiatives to educate policymakers about diagnostics and personalized medicine. Most recently, she co-founded the International School of Biomedical Diagnostics at Arizona State University and Dublin City University, the first school dedicated to Diagnostics as an independent discipline. She also founded DxInsights, an institute committed to expanding knowledge on the importance of diagnostics in improving patient care, as well as the European Personalized Medicine Association (EPEMED), and acted as a former Director of the U.S. Personalized Medicine Coalition (PMC).
Ms. Aspinall has served on several committees throughout her career, including 15 years on the board of the Dana Farber Cancer Institute, chairing the Science Committee, Blue Cross Blue Shield Massachusetts, and the Secretary of Health and Human Services’ Advisory Council on Genetics for both the Obama and Bush administrations. Today, Ms. Aspinall chairs the Arizona Biosciences Board, a group led by CEOs in multiple industries dedicated to improving the state’s atmosphere for technology companies.
Ms. Aspinall holds an MBA from Harvard Business School and a BA in International Relations from Tufts University.
Joe Cook has served as a director for Castle Biosciences since 2012, and was an advisor to the company from 2008 until becoming a director. He is a principal and co-founder of Mountain Group Capital. He is a founder and former Chairman of the Board of Ironwood Pharmaceuticals, Inc., where he continues to serve as a Director. He also serves as a director of Corcept Therapeutics, Inc.
Mr. Cook served as Chairman of Amylin Pharmaceuticals, Inc. from 1998 to 2009 and was Chief Executive Officer from 1998 to 2003. In 2009, Mr. Cook received the Pinnacle Award for Life Science Leadership from the Rady School of Management at the University of California at San Diego.
Mr. Cook retired as a Group Vice President, Global Operations, of Eli Lilly and Company in 1993 after more than 28 years of service. During his career at Lilly he served in various senior executive positions, including manufacturing, engineering, finance, sales and marketing and general management. Mr. Cook took a leave of absence from Eli Lilly and Co. in 1976 to serve on the U.S. International Trade Commission in Washington, D.C. as a part of the President’s Executive Exchange Program.
Mr. Cook serves as Chairman of the Board of Mercy Ministries International, Inc. He is also a former Chair and current member of the University of Tennessee College of Engineering Advisory Board. In 1999, Mr. Cook received the Nathan W. Dougherty Award from the University of Tennessee for distinguished service in the engineering profession. Mr. Cook also serves on the national board of the American Diabetes Association and is Chairman of the Board of Life Science Tennessee. He also serves as Chairman of Diabetes Care Group and on the Board of Clinical Products. He was a co-founder and serves on the boards of Device Innovation Group and Diagnovus.
Mr. Cook graduated from the University of Tennessee in 1965 where he received a BS in Engineering with High Honors and was a U.T. Torchbearer.
David Kabakoff has served a director for Castle Biosciences since September 2017, and was previously an observer to the board. He has been a Partner in HealthQuest Capital since 2013 and an Executive Partner with Sofinnova since 2007. Dr. Kabakoff has more than 30 years of experience leading technology and product development programs in the pharmaceutical, biopharmaceutical, diagnostics, and drug delivery fields. Dr. Kabakoff currently serves as Chairman of NextCure, Chairman of Lineagen, as a Director of Antiva Biosciences, Dauntless Pharmaceuticals, BioClin Therapeutics and BioTheranostics. Formerly he served as Chairman of Trius Therapeutics (acquired by Cubist), Chairman of Amplimmune (acquired by Astra Zeneca), as a Director of InterMune, Inc. (acquired by Roche), and Director of Allylix, Inc. (acquired by Evolva). Dr. Kabakoff also served as a Board Observer at Intellikine (acquired by Takeda).
Dr. Kabakoff co-founded Salmedix, Inc., a developer of cancer drugs, and served as Chairman and Chief Executive Officer (acquired by Cephalon Inc.). He also held the positions of Executive Vice President of Dura, a specialty respiratory pharmaceutical and pulmonary drug delivery company, and President and Chief Executive Officer of Spiros Development Corp. Prior to Dura, Dr. Kabakoff was Chief Executive Officer of Corvas International and held senior executive positions with Hybritech, Inc.
Dr. Kabakoff received his PhD from Yale University and his BA from Case Western Reserve University.